Do analysts recommend RYOJ or LFMD?

LifeMD has a consensus target price of $7.57, indicating a potential upside of 187.89%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has preferable earnings & valuation, RYOJ or LFMD?

LifeMD has higher revenue and earnings than RYOJ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 3.42 $120K N/A N/A LifeMD $194.05M 0.65 $14.35M -$0.05 N/A

Is RYOJ or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to RYOJ's net margin of 0.00%. RYOJ's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A LifeMD 0.10% -168.23% -31.27%

Do analysts prefer RYOJ or JYNT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings and valuation, RYOJ or JYNT?

Joint has higher revenue and earnings than RYOJ. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 3.42 $120K N/A N/A Joint $54.90M 1.81 $2.91M $0.27 26.07

Is RYOJ or JYNT more profitable?

Joint has a net margin of 6.49% compared to RYOJ's net margin of 0.00%. Joint's return on equity of 12.02% beat RYOJ's return on equity. Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A Joint 6.49% 12.02% 3.47%

Do analysts prefer RYOJ or PARK?

Park Dental Partners has a consensus target price of $28.50, indicating a potential upside of 40.74%. Given Park Dental Partners' stronger consensus rating and higher possible upside, analysts plainly believe Park Dental Partners is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Park Dental Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, RYOJ or PARK?

RYOJ has higher earnings, but lower revenue than Park Dental Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 3.42 $120K N/A N/A Park Dental Partners $244.49M 0.39 -$360K $1.05 19.29

Is RYOJ or PARK more profitable?

Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A Park Dental Partners N/A N/A N/A

Do analysts prefer RYOJ or PIII?

P3 Health Partners has a consensus price target of $17.00, indicating a potential upside of 243.43%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, RYOJ or PIII?

RYOJ has higher earnings, but lower revenue than P3 Health Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 3.42 $120K N/A N/A P3 Health Partners $1.50B 0.02 -$147.95M -$33.00 N/A

Is RYOJ or PIII more profitable?

RYOJ has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%. Company Net Margins Return on Equity Return on Assets RYOJ N/A N/A N/A P3 Health Partners -6.55% N/A -16.40%

Do analysts recommend RYOJ or ACH?

Accendra Health has a consensus target price of $1.50, indicating a potential upside of 253.94%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than RYOJ. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYOJ 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Accendra Health 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60

Which has stronger valuation and earnings, RYOJ or ACH?

RYOJ has higher earnings, but lower revenue than Accendra Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYOJ $9.34M 3.42 $120K N/A N/A Accendra Health $2.73B 0.01 -$1.10B -$3.91 N/A

RYOJ (RYOJ) Competitors

$2.77 -0.14 (-4.95%)

Closing price 10/9/2026 03:54 PM Eastern

Extended Trading

$2.77 +0.00 (+0.14%)

As of 10/9/2026 06:13 PM Eastern

Compare

RYOJ vs. LFMD, JYNT, PARK, PIII, and ACH

Should you buy RYOJ stock or one of its competitors? RYOJ's main competitors and comparable companies include LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), P3 Health Partners (PIII), and Accendra Health (ACH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does RYOJ compare to LifeMD?

RYOJ (NASDAQ:RYOJ) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, RYOJ had 1 more articles in the media than LifeMD. MarketBeat recorded 2 mentions for RYOJ and 1 mentions for LifeMD. LifeMD's average media sentiment score of 0.67 beat RYOJ's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Overall Sentiment
RYOJ	Neutral
LifeMD	Positive

RYOJ has a beta of 4.54, meaning that its stock price is 354% more volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

LifeMD has a net margin of 0.10% compared to RYOJ's net margin of 0.00%. RYOJ's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
LifeMD	0.10%	-168.23%	-31.27%

LifeMD has higher revenue and earnings than RYOJ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	3.42	$120K	N/A	N/A
LifeMD	$194.05M	0.65	$14.35M	-$0.05	N/A

35.5% of LifeMD shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

LifeMD has a consensus target price of $7.57, indicating a potential upside of 187.89%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

LifeMD beats RYOJ on 9 of the 14 factors compared between the two stocks.

How does RYOJ compare to Joint?

RYOJ (NASDAQ:RYOJ) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Joint has higher revenue and earnings than RYOJ.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	3.42	$120K	N/A	N/A
Joint	$54.90M	1.81	$2.91M	$0.27	26.07

RYOJ has a beta of 4.54, suggesting that its share price is 354% more volatile than the broader market. Comparatively, Joint has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

In the previous week, Joint had 1 more articles in the media than RYOJ. MarketBeat recorded 3 mentions for Joint and 2 mentions for RYOJ. RYOJ's average media sentiment score of 0.00 equaled Joint'saverage media sentiment score.

Company	Overall Sentiment
RYOJ	Neutral
Joint	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Joint has a net margin of 6.49% compared to RYOJ's net margin of 0.00%. Joint's return on equity of 12.02% beat RYOJ's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Joint	6.49%	12.02%	3.47%

76.9% of Joint shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Joint beats RYOJ on 9 of the 11 factors compared between the two stocks.

How does RYOJ compare to Park Dental Partners?

RYOJ (NASDAQ:RYOJ) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

RYOJ has higher earnings, but lower revenue than Park Dental Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	3.42	$120K	N/A	N/A
Park Dental Partners	$244.49M	0.39	-$360K	$1.05	19.29

Park Dental Partners has a consensus target price of $28.50, indicating a potential upside of 40.74%. Given Park Dental Partners' stronger consensus rating and higher possible upside, analysts plainly believe Park Dental Partners is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, RYOJ and RYOJ both had 2 articles in the media. RYOJ's average media sentiment score of 0.00 equaled Park Dental Partners'average media sentiment score.

Company	Overall Sentiment
RYOJ	Neutral
Park Dental Partners	Neutral

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Park Dental Partners	N/A	N/A	N/A

Summary

Park Dental Partners beats RYOJ on 5 of the 7 factors compared between the two stocks.

How does RYOJ compare to P3 Health Partners?

RYOJ (NASDAQ:RYOJ) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

P3 Health Partners has a consensus price target of $17.00, indicating a potential upside of 243.43%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

RYOJ has a beta of 4.54, suggesting that its stock price is 354% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

RYOJ has higher earnings, but lower revenue than P3 Health Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	3.42	$120K	N/A	N/A
P3 Health Partners	$1.50B	0.02	-$147.95M	-$33.00	N/A

7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, P3 Health Partners had 1 more articles in the media than RYOJ. MarketBeat recorded 3 mentions for P3 Health Partners and 2 mentions for RYOJ. RYOJ's average media sentiment score of 0.00 equaled P3 Health Partners'average media sentiment score.

Company	Overall Sentiment
RYOJ	Neutral
P3 Health Partners	Neutral

RYOJ has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
P3 Health Partners	-6.55%	N/A	-16.40%

Summary

P3 Health Partners beats RYOJ on 7 of the 12 factors compared between the two stocks.

How does RYOJ compare to Accendra Health?

RYOJ (NASDAQ:RYOJ) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

RYOJ has a net margin of 0.00% compared to Accendra Health's net margin of -11.41%. RYOJ's return on equity of 0.00% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYOJ	N/A	N/A	N/A
Accendra Health	-11.41%	-4.02%	0.70%

RYOJ has higher earnings, but lower revenue than Accendra Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYOJ	$9.34M	3.42	$120K	N/A	N/A
Accendra Health	$2.73B	0.01	-$1.10B	-$3.91	N/A

RYOJ has a beta of 4.54, suggesting that its stock price is 354% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Accendra Health has a consensus target price of $1.50, indicating a potential upside of 253.94%. Given Accendra Health's stronger consensus rating and higher probable upside, analysts clearly believe Accendra Health is more favorable than RYOJ.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYOJ	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Accendra Health	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

In the previous week, Accendra Health had 1 more articles in the media than RYOJ. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for RYOJ. RYOJ's average media sentiment score of 0.00 beat Accendra Health's score of -0.67 indicating that RYOJ is being referred to more favorably in the media.

Company	Overall Sentiment
RYOJ	Neutral
Accendra Health	Negative

Summary

RYOJ beats Accendra Health on 6 of the 11 factors compared between the two stocks.

Get RYOJ News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYOJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYOJ vs. The Competition

Export

Metric	RYOJ	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.61M	$9.81B	$7.16B	$13.21B
Dividend Yield	N/A	2.61%	2.53%	16.36%
P/E Ratio	N/A	33.98	274.15	26.16
Price / Sales	3.42	4.87	590.34	94.78
Price / Cash	56.44	115.75	76.38	53.09
Price / Book	5.12	5.11	11.21	6.34
Net Income	$120K	$315.68M	$3.50B	$381.90M
7 Day Performance	-2.95%	-0.38%	-0.90%	-1.41%
1 Month Performance	-41.15%	-1.97%	-4.44%	-3.48%
1 Year Performance	N/A	12.76%	6.96%	1.16%

RYOJ Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYOJ RYOJ	0.4524 of 5 stars	$2.77 -4.9%	N/A	N/A	$33.61M	$9.34M	N/A	313	Short Interest Decrease
LFMD LifeMD	2.8497 of 5 stars	$2.74 -3.9%	$7.57 +176.3%	-59.7%	$137.37M	$194.05M	N/A	384
JYNT Joint	1.766 of 5 stars	$7.28 -2.5%	N/A	-17.0%	$105.65M	$54.90M	26.96	330
PARK Park Dental Partners	3.3403 of 5 stars	$19.84 -1.3%	$28.50 +43.6%	N/A	$95.63M	$244.49M	N/A	1,212	Positive News Short Interest Increase
PIII P3 Health Partners	2.1399 of 5 stars	$6.36 +1.4%	$17.00 +167.3%	-45.9%	$45.53M	$1.46B	N/A	320	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYOJ) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RYOJ (RYOJ) Competitors

RYOJ vs. LFMD, JYNT, PARK, PIII, and ACH

How does RYOJ compare to LifeMD?

Summary

How does RYOJ compare to Joint?

Summary

How does RYOJ compare to Park Dental Partners?

Summary

How does RYOJ compare to P3 Health Partners?

Summary

How does RYOJ compare to Accendra Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYOJ vs. The Competition

RYOJ Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RYOJ (RYOJ) Competitors

RYOJ vs. LFMD, JYNT, PARK, PIII, and ACH

How does RYOJ compare to LifeMD?

Does the media refer more to RYOJ or LFMD?

Which has more risk and volatility, RYOJ or LFMD?

Is RYOJ or LFMD more profitable?

Which has preferable earnings & valuation, RYOJ or LFMD?

Do institutionals and insiders believe in RYOJ or LFMD?

Do analysts recommend RYOJ or LFMD?

Summary

How does RYOJ compare to Joint?

Which has higher earnings and valuation, RYOJ or JYNT?

Which has more volatility and risk, RYOJ or JYNT?

Does the media favor RYOJ or JYNT?

Do analysts prefer RYOJ or JYNT?

Is RYOJ or JYNT more profitable?

Do institutionals & insiders have more ownership in RYOJ or JYNT?

Summary

How does RYOJ compare to Park Dental Partners?

Which has preferable valuation and earnings, RYOJ or PARK?

Do analysts prefer RYOJ or PARK?

Does the media prefer RYOJ or PARK?

Is RYOJ or PARK more profitable?

Summary

How does RYOJ compare to P3 Health Partners?

Do analysts prefer RYOJ or PIII?

Which has more risk and volatility, RYOJ or PIII?

Which has stronger earnings & valuation, RYOJ or PIII?

Do insiders and institutionals have more ownership in RYOJ or PIII?

Does the media refer more to RYOJ or PIII?

Is RYOJ or PIII more profitable?

Summary

How does RYOJ compare to Accendra Health?

Is RYOJ or ACH more profitable?

Which has stronger valuation and earnings, RYOJ or ACH?

Which has more volatility & risk, RYOJ or ACH?

Do analysts recommend RYOJ or ACH?

Does the media favor RYOJ or ACH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYOJ vs. The Competition

RYOJ Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools